Pharma Stock Roundup: PFE's 2025 Outlook, MRK & ABBV's M&A Deals [Yahoo! Finance]
Merck & Company, Inc. (new) (MRK)
Last merck & company, inc. (new) earnings: 4/28 06:45 am
Check Earnings Report
US:NYSE Investor Relations:
investors.merck.com/home/default.aspx
Company Research
Source: Yahoo! Finance
Sanofi SNY and Teva Pharmaceutical's TEVA inflammatory bowel disease (IBD) study on their candidate, duvakitug (TEV'574), met its primary endpoints. Merck MRK inked an exclusive global licensing deal with China's Hansoh Pharma for the latter's oral GLP-1-based obesity candidate. AbbVie ABBV also announced an acquisition in the immunology space. Here's a recap of the week's most important stories. Pfizer Issues 2025 Financial Outlook Pfizer announced encouraging guidance for 2025. In 2025, Pfizer expects to record total revenues between $61.0 billion and $64.0 billion. On an operational basis, revenues in 2025 are expected to rise in a range of approximately flat to 5% from the midpoint of 2024 guidance, excluding the impact of approximately $1.2 billion of non-recurring revenues for Paxlovid. Adjusted earnings are expected in the range of $2.80-$3.00, representing expected operational growth (excluding the Fx impact) in the range of 10%-18% year over year from the midpoint of
Show less
Read more
Impact Snapshot
Event Time:
MRK
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MRK alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MRK alerts
High impacting Merck & Company, Inc. (new) news events
Weekly update
A roundup of the hottest topics
MRK
News
- More on MRK's HIV-1 Program [Yahoo! Finance]Yahoo! Finance
- Merck & Co., Inc. (MRK) is Attracting Investor Attention: Here is What You Should Know [Yahoo! Finance]Yahoo! Finance
- BMO cuts rating on Merck and Biogen, on lack of near term catalyst [Yahoo! Finance]Yahoo! Finance
- Investing in Merck (NYSE:MRK) three years ago would have delivered you a 43% gain [Yahoo! Finance]Yahoo! Finance
- Merck & Co., Inc. (NYSE: MRK) was downgraded by analysts at BMO Capital Markets from an "outperform" rating to a "market perform" rating. They now have a $105.00 price target on the stock, down previously from $136.00.MarketBeat
MRK
Earnings
- 10/31/24 - Beat
MRK
Sec Filings
- 11/22/24 - Form 8-K
- 11/6/24 - Form 10-Q
- 11/4/24 - Form 25-NSE
- MRK's page on the SEC website